Similarly, in this study, it was clarified that the interaction between OX40 and OX40L is greatly involved in the pathophysiology of MF/SS, which led us to expect that anti-OX40 and anti-OX40L antibodies could be promising therapeutics for MF/SS. The gene discussed is TNFRSF4; the disease is mycosis fungoides.